The deal – announced at the JP Morgan Healthcare conference this week – includes a sizeable $1 billion upfront payment, with up to $400 million more on the table if Aiolos’ pipeline delivers the results GSK is hoping for.
AIO-001 is a long-acting monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a drug in the same class as AstraZeneca’s first-to-market Tezspire (tezepelumab), which was approved by the FDA for severe asthma towards the end of 2021.
